Quadrant Capital Group LLC Purchases 2,177 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Quadrant Capital Group LLC raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIRFree Report) by 274.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,970 shares of the company’s stock after purchasing an additional 2,177 shares during the period. Quadrant Capital Group LLC’s holdings in Vir Biotechnology were worth $30,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Vir Biotechnology by 9.4% during the 3rd quarter. Vanguard Group Inc. now owns 11,200,666 shares of the company’s stock valued at $104,950,000 after purchasing an additional 960,302 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Vir Biotechnology by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,073 shares of the company’s stock valued at $7,576,000 after purchasing an additional 31,405 shares during the last quarter. Jupiter Asset Management Ltd. boosted its stake in Vir Biotechnology by 41.0% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 708,257 shares of the company’s stock valued at $6,636,000 after purchasing an additional 205,913 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in Vir Biotechnology by 68.5% during the 3rd quarter. Rafferty Asset Management LLC now owns 525,317 shares of the company’s stock valued at $4,922,000 after purchasing an additional 213,477 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Vir Biotechnology by 8.4% during the 3rd quarter. Principal Financial Group Inc. now owns 511,692 shares of the company’s stock valued at $4,795,000 after purchasing an additional 39,762 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Backer Marianne De sold 72,995 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total value of $690,532.70. Following the sale, the chief executive officer now owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Backer Marianne De sold 72,995 shares of Vir Biotechnology stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the completion of the transaction, the chief executive officer now directly owns 678,457 shares in the company, valued at $6,418,203.22. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Ann M. Hanly sold 2,711 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $10.05, for a total value of $27,245.55. Following the sale, the executive vice president now owns 132,069 shares in the company, valued at $1,327,293.45. The disclosure for this sale can be found here. Insiders sold 81,714 shares of company stock worth $777,197 over the last quarter. 15.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

VIR has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, May 24th. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Vir Biotechnology in a research note on Friday, May 3rd. Finally, JPMorgan Chase & Co. boosted their target price on Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.57.

Check Out Our Latest Stock Report on Vir Biotechnology

Vir Biotechnology Trading Up 1.7 %

Vir Biotechnology stock opened at $10.73 on Wednesday. The business’s 50 day simple moving average is $9.47 and its 200 day simple moving average is $9.83. Vir Biotechnology, Inc. has a 12 month low of $7.61 and a 12 month high of $27.48.

Vir Biotechnology (NASDAQ:VIRGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.51. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The firm had revenue of $56.38 million for the quarter, compared to analysts’ expectations of $11.71 million. During the same quarter in the prior year, the firm earned ($1.06) EPS. The business’s revenue for the quarter was down 10.5% compared to the same quarter last year. Sell-side analysts expect that Vir Biotechnology, Inc. will post -3.42 earnings per share for the current fiscal year.

Vir Biotechnology Company Profile

(Free Report)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.

Read More

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRFree Report).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.